Friday, July 10, 2026

pharma · Muscle-invasive bladder cancer (MIBC) · Acute ischaemic stroke due to basilar artery occlusion.

Tour Hekla

Tour Hekla clinical programs — 0 development programs from ClinicalTrials.gov with phase, modality, indication, and trial identifiers.

Puteaux, Ile de France 92800, FR HQ
6 Employees
EMA registrant Type
Company details
Status
Public
HQ
Puteaux, Ile de France 92800, FR
Employees
6
Programs
27
Drugs
71
Patents
0
Intelligence · Clinical Programs

Tour Hekla projects

0 ClinicalTrials.gov programs sponsored by Tour Hekla.

Tour Hekla has 0 clinical development programs indexed from ClinicalTrials.gov, including phase, modality, indication text, and linked NCT identifiers.

No programs matched

Try a different phase filter or check back as we index more trials.

Frequently asked questions

How many clinical projects does Tour Hekla have?

0 published programs are linked to this sponsor in our ClinicalTrials.gov index.

Is this the complete company pipeline?

This directory lists published programs for the sponsor in our database. Partnered or out-licensed assets may appear under multiple companies.